Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Press

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for…

Market Research

Psychedelics Effects on Sexual Functions

In the mid-20th century, psychedelic substances like LSD were explored for treating mood disorders and alcohol dependence. Their association with the 1960s ‘hippy’ movement led to a halt in research, but recent years have seen a revival, especially in treating anxiety and depression. Major depressive disorder (MDD), often accompanied by sexual dysfunction (SD), significantly impacts…

Press Release Press

Avesta Partners with Veterans Affairs (VA) to Offer Free Ketamine Therapy to Eligible Veterans

WASHINGTON, Feb. 21, 2024 /PRNewswire/ — Avesta Ketamine and Wellness (“Avesta”), a leading provider of innovative mental health treatments, announced a partnership with Veterans Affairs (VA) to offer free ketamine therapy to eligible veterans. This initiative, available now in Avesta ketamine clinics across Washington, DC, Northern Virginia, and Bethesda, Maryland, will help veterans overcome treatment-resistant depression (TRD), PTSD, anxiety, chronic…

Press

FSD Pharma Inc. (NASDAQ: HUGE) Enters Market Offering Agreement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an agreement. The market offering agreement is with H.C. Wainwright & Co. LLC. According to the agreement, FSD Pharma may offer and sell Class B subordinate voting shares in the…

Market Research

Illinois Embarks on a Legalization Journey for Psilocybin Therapy

In a progressive move towards mental health innovation, Illinois State Senator Rachel Ventura, a Democrat, has recently introduced a groundbreaking bill. Titled the Compassionate Use and Research of Entheogens (CURE) Act, this legislation, introduced earlier this month, could potentially transform mental health treatment in the state. Senate Bill 3695: A Beacon of Hope for Mental…

Clearmind Press

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has submitted three patent applications under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing…

Market Research

Save the Date: Psychedelic Science Returns in 2025

Denver is set to host the illustrious Psychedelic Science Conference in 2025, organized by the esteemed Multidisciplinary Association for Psychedelic Studies (MAPS). This grand event will take place at the Colorado Convention Center from June 16th to June 20th, 2025. Known for its rich history in hosting groundbreaking conferences, this will mark the fifth iteration…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.